Skip to main content
. 2015 Jul 14;19(10):2341–2351. doi: 10.1111/jcmm.12638

Figure 2.

Figure 2

Effects of BM-MSCs on permeability and inflammation in IRI-challenged lungs. Administration of BM-MSCs reduced the level of lung oedema and inflammation compared to the IRI group (n = 6 for each group). (A) Treatment with BM-MSCs reduced the wet/dry ratio compared to the IRI group. (B) Pre-conditioning with BM-MSCs attenuated the level of protein in the BALF compared to the IRI group. (C) BM-MSCs decreased the level of IL-1β in the BALF fluid of IRI mice. (D) BM-MSCs decreased the level of TNF-α in the BALF fluid of IRI mice. Data are expressed as the mean ± SD. *P < 0.05 versus control group; #P < 0.05 versus IRI group by anova (Bonferroni).